Hyperthermia Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Device Type (Microwave Hyperthermia Device, Ultrasound Hyperthermia Device, Infrared Hyperthermia Device, Short-wave Hyperthermia Device),

Hyperthermia Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Device Type (Microwave Hyperthermia Device, Ultrasound Hyperthermia Device, Infrared Hyperthermia Device, Short-wave Hyperthermia Device), By Application (Prostate Cancer, Breast Cancer, Cervical Cancer, Skin Cancer, Other Cancers), By End User (Hospitals & Clinics, Specialty Centers, Others), By Region and Competition, 2019-2029F

Global Hyperthermia Cancer Treatment Market was valued at USD 151.26 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.62% through 2029. Hyperthermia cancer treatment involves intentionally heating the body or specific tumor tissues to temperatures typically ranging from 40°C to 45°C (104°F to 113°F). This therapeutic method targets and potentially destroys cancer cells, whether applied locally, regionally, or across the entire body. This heat-based approach not only increases the effectiveness of concurrent cancer treatments like radiation therapy or chemotherapy but also enhances the delivery of these therapies by boosting blood flow to the tumor site, facilitating better oxygen and drug transport to cancer cells. Additionally, hyperthermia has been observed to stimulate the body's immune response against cancer, potentially aiding in the recognition and destruction of tumors.

Hyperthermia treatments are administered using various methods, including external or internal heating devices, microwave applicators, or warm water blankets. Despite being a relatively small segment of the oncology market currently, hyperthermia is gaining traction as technological advancements improve treatment precision and effectiveness. However, widespread awareness among patients and healthcare providers about hyperthermia as a viable treatment option remains limited.

Integrating hyperthermia with chemotherapy, radiation therapy, and surgical procedures presents logistical challenges but holds promise in enhancing overall treatment outcomes. As awareness grows and technological integration advances, hyperthermia is expected to play a more prominent role in global cancer treatment strategies, offering new avenues of hope in the battle against cancer.

Key Market Drivers

Increasing Cancer Incidence

The rising incidence of cancer globally has created a larger population in need of effective treatment options. Hyperthermia offers an alternative or supplementary approach to traditional therapies such as chemotherapy and radiation, particularly beneficial for cancers that are resistant to standard treatments. According to a report from WHO, approximately 1 in 5 people develop cancer during their lifetime, with 1 in 9 men and 1 in 12 women succumbing to the disease. Disparities based on the Human Development Index (HDI) indicate that countries with higher HDI levels are projected to experience a significant increase in new cases by 2050 compared to countries with lower HDI levels.

There is a growing demand for innovative therapies like hyperthermia driven by the need to improve treatment efficacy and enhance patient outcomes. Hyperthermia equips healthcare providers with additional tools to combat cancer, especially in cases where traditional therapies have limited effectiveness, thereby expanding the range of treatment options available to clinicians and patients. Clinical studies and trials have demonstrated that combining hyperthermia with other treatments can boost therapeutic effectiveness and potentially improve survival rates, making it an attractive choice for managing various types of cancers.

Regulatory bodies are increasingly recognizing hyperthermia as a safe and effective treatment option when used in conjunction with standard therapies. This recognition facilitates easier adoption and integration of hyperthermia into clinical practice. The growing global incidence of cancer underscores the critical need for effective treatments, driving the expansion of the hyperthermia cancer treatment market by broadening its applicability and acceptance within oncology practices.

Growing Research and Development

Increased research and development efforts lead to advancements in hyperthermia treatment technologies and techniques, resulting in the creation of more effective and precise devices for heating tumors or specific tissues, thereby enhancing treatment outcomes. A team of researchers from China has developed adjuvant biomaterials to enhance Microwave Ablation (MWA), which holds practical significance. Their work demonstrates that alginate-based hydrogels with high Ca2+ concentration improve heating efficiency and limit the heating zone under microwave exposure. This approach synergizes with mild hyperthermia to induce immunogenic cell death by disrupting intracellular Ca2+ balance. The combination of Ca2+-surplus alginate hydrogel with MWA effectively ablates various tumors in animal models using reduced power levels. This study underscores the potential of metallo-alginate hydrogel as a microwave-responsive and immunostimulatory biomaterial to augment MWA therapy, showing promise for clinical application.

Research and development also facilitate exploring new applications and combinations of hyperthermia with therapies like chemotherapy, radiation therapy, and immunotherapy. This expands the scope of hyperthermia across different cancer types and stages. For instance, in 2024, Amrita Hospital in Faridabad, India, announced a government-funded initiative to develop a robot-assisted ultrasound system for image-guided therapies and hyperthermia in cancer treatment, led by the head of their Radiation Oncology department. They partnered with IIT Hyderabad and Eranki Labs Private Limited for the project. This interdisciplinary collaboration is essential for advancing cancer care technology, focusing on a comprehensive approach to innovating treatment. The project, expected to conclude in three years, received funding from the Indian Council of Medical Research (ICMR).

Continued research validates the efficacy and safety of hyperthermia, crucial for obtaining regulatory approvals and increasing acceptance among healthcare providers. For example, a 2024 study published in Nature demonstrated that inhibiting heat shock factor 1 enhances the effects of modulated electro hyperthermia in a triple negative breast cancer mouse model, highlighting ongoing advancements. The focus on research and development in hyperthermia cancer treatment drives technological progress and expands the market by addressing unmet medical needs and improving outcomes for cancer patients worldwide.

Key Market Challenges

Cost and Reimbursement Issues

Implementing hyperthermia treatment necessitates specialized equipment like electromagnetic or ultrasound devices capable of heating tumors to therapeutic temperatures, which are costly to acquire and maintain, necessitating substantial initial investment for healthcare facilities. Alongside equipment costs, there are ongoing operational expenses including regular maintenance, calibration, and the requirement for trained personnel to effectively operate and oversee treatment sessions. Each hyperthermia session contributes to the overall expense of cancer care, which can be considerable, particularly when combined with conventional treatments such as radiation therapy or chemotherapy. Patients undergoing multiple sessions may face significant cumulative financial burdens.

Securing adequate reimbursement for hyperthermia treatments from healthcare payers, such as insurance companies or government health programs, poses challenges. Reimbursement rates often fall short of covering treatment costs, potentially resulting in financial losses for healthcare providers or increased out-of-pocket expenses for patients. The high cost of hyperthermia treatment can restrict patient access, especially in regions with limited healthcare resources or within healthcare systems that do not fully cover such specialized treatments. This disparity can lead to unequal access to potentially beneficial therapies based on financial considerations rather than medical necessity. Addressing the cost challenge in the hyperthermia cancer treatment market requires a multifaceted approach. This includes leveraging technological innovations to reduce equipment and operational costs, advocating for improved reimbursement policies, generating clinical evidence demonstrating cost-effectiveness, and implementing initiatives to improve affordability and accessibility for patients.

Complexity and Technical Challenges

Hyperthermia treatment involves heating tumors to specific therapeutic temperatures (typically between 40-45°C) while minimizing harm to surrounding healthy tissues. Achieving and maintaining these temperatures is crucial in treating deep-seated tumors like pelvic or abdominal cancers, such as in prostate cancer where precision is necessary to avoid damage to adjacent organs like the bladder or rectum. Engineers designing microwave applicators for hyperthermia must ensure they emit controlled electromagnetic waves that penetrate tissues uniformly. They encounter challenges in delivering sufficient heat to deep tumors without overheating superficial tissues, but advancements like phased array applicators improve heat distribution and treatment effectiveness.

Hyperthermia treatment protocols vary depending on factors such as tumor type, size, and location. For instance, treating cervical cancer might involve combining hyperthermia with radiation therapy. Standardizing protocols across different facilities is difficult due to equipment variability, varying expertise, and patient diversity. Operating hyperthermia equipment requires specialized training in heat transfer principles, thermal dosimetry, and patient care during sessions. Maintaining an adequately trained workforce can be challenging, particularly in smaller healthcare settings with limited training resources.

Ensuring the safety and effectiveness of hyperthermia involves rigorous quality assurance, including regular equipment maintenance, calibration, and adherence to treatment protocols. Maintaining consistent quality across diverse healthcare providers and facilities is challenging, affecting treatment reliability and patient outcomes. Ongoing research focuses on overcoming technical obstacles and refining hyperthermia treatments. For example, researchers explore novel heat delivery methods like magnetic nanoparticles heated by external magnetic fields, enabling precise tumor targeting.

Key Market Trends

Focus on Combination Therapies

Hyperthermia complements chemotherapy and radiation therapy by increasing the susceptibility of cancer cells to these treatments. Elevated temperatures promote enhanced blood flow to tumors, facilitating improved delivery of chemotherapy drugs and oxygen, thereby boosting treatment efficacy. A preclinical study conducted by researchers at the UCLA Jonsson Comprehensive Cancer Center has suggested that heating solid tumors during CAR T-cell therapy can amplify treatment success. Clinical studies affirm the effectiveness of hyperthermia in combination therapies, prompting ongoing research and adoption by healthcare providers. In their research, scientists found that combining photothermal ablation with CAR T-cell infusion suppressed melanoma tumor growth in mice for up to 20 days, with 33 percent remaining tumor-free thereafter. The study tested mild hyperthermia at approximately 40 degrees Celsius (104 degrees Fahrenheit) to enhance CAR T-cell activity against tumors. Published in Advanced Materials, this research underscores how advances in hyperthermia technology, including improved heating devices and treatment planning systems, facilitate its safe and effective integration into combination therapies.

Magnetic hyperthermia-based cancer therapy (MHCT) has shown therapeutic potential but faces challenges such as low reactive oxygen species (ROS) generation in hypoxic tumor microenvironments and inefficient heat transmission. Dr. Deepika Sharma and her team at the Institute of Nano Science and Technology (INST), Mohali, addressed these issues by developing a vitamin K3-loaded copper zinc ferrite-based magneto thermodynamic treatment. This innovative approach combines magnetic hyperthermia and chemodynamic therapy, leveraging ROS from magneto thermodynamics to induce irreversible oxidative damage to tumor cells, resulting in complete tumor eradication within 30 days. Their findings, published in ACS Applied Materials & Interfaces in 2023, highlight significant advancements in cancer treatment strategies.

In the context of advanced ovarian cancer, chemo-hyperthermia has emerged with promising outcomes. Hyperthermia administered alongside chemotherapy sensitizes cancer cells, enhancing the drugs' effectiveness. Preclinical studies also indicate hyperthermia's potential to stimulate immune cells, augmenting their ability to recognize and attack cancer cells when combined with immune checkpoint inhibitors. This multifaceted approach is currently under investigation in clinical trials across various cancers like melanoma and renal cell carcinoma, driven by the pursuit of improved treatment outcomes, minimized side effects, and innovative cancer management strategies.

Segmental Insights

Device Type Insights

Based on Device Type, the Microwave Hyperthermia Device emerged as the dominating segment in the global market for Hyperthermia Cancer Treatment in 2023. This is due to their ability to deeply penetrate tissues with electromagnetic waves, effectively heating both superficial and deep-seated tumors essential for treating various cancers at different depths within the body. These devices are versatile, suitable for a wide range of clinical applications including breast, prostate, head and neck cancers, among others. Their widespread adoption in clinical settings is bolstered by continuous technological advancements, broad commercial availability, regulatory approvals, and adherence to clinical guidelines. In 2023, Pyrexar Medical renewed the CE mark for their RF Hyperthermia Systems product line, which includes the BSD-500 Superficial/Interstitial Hyperthermia System, BSD-2000, BSD-2000 3D, and BSD-2000 3D/MR Deep Regional Hyperthermia System.

Application Insights

Based on Application Type, Breast Cancer emerged as the fastest growing segment in the global market for Hyperthermia Cancer Treatment during forecast period. Hyperthermia has demonstrated considerable effectiveness in treating breast cancer when used alongside chemotherapy and radiation therapies. This method allows tumors to be heated precisely while sparing healthy surrounding tissues, thereby minimizing the systemic side effects typically associated with conventional cancer treatments. These benefits significantly enhance the quality of life for breast cancer patients undergoing therapy. Hyperthermia's precise targeting enables tumors to be heated with accuracy, minimizing damage to surrounding healthy tissues. This focused treatment approach reduces the systemic side effects often linked with conventional cancer therapies, thus enhancing the overall quality of life for breast cancer patients undergoing treatment. Advancements in hyperthermia technology have been particularly focused on developing devices that can deliver controlled heat specifically to breast tumors. According to projections by the International Agency for Research on Cancer (IARC), the global incidence of breast cancer is expected to exceed 3 million new cases annually by 2040, solidifying its position as the second most prevalent cancer worldwide. In the United States, the American Cancer Society reports that the average lifetime risk for women developing breast cancer is around 13%, equating to a 1 in 8 chance. This high prevalence underscores a growing demand for hyperthermia treatments and heat treatment equipment, thereby driving growth in this segment of the market.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Hyperthermia Cancer Treatment Market in 2023. This stems from its advanced healthcare infrastructure, robust research capabilities, supportive regulatory environment, high cancer incidence rates, substantial healthcare expenditures, clinical expertise, and strong patient demand. According to the National Cancer Institute (NCI), it is projected that in 2024, approximately 2,001,140 new cancer cases will be diagnosed in the United States, with an estimated 611,720 deaths from the disease. Among men, prostate, lung, and colorectal cancers are anticipated to comprise 48% of new diagnoses, while breast, lung, and colorectal cancers are expected to account for 51% of new diagnoses among women. In 2020, expenditures for cancer care in the United States alone totaled $208.9 billion, with costs expected to rise as the population ages and cancer incidence increases. North America's significant healthcare spending facilitates substantial investments in innovative cancer treatments, including advanced technologies like hyperthermia devices. Stringent regulatory frameworks, particularly in the United States, ensure the safety and effectiveness of medical devices and treatments, including hyperthermia systems. Patients in North America are well-informed about various cancer treatment options and actively seek advanced therapies that promise improved outcomes and enhanced quality of life. This informed patient base contributes to the region's high demand for hyperthermia treatments. The United States and Israel will receive $8.4 million in funding from the Israel-US Binational Industrial Research and Development (BIRD) Foundation for nine projects. Among these projects, New Phase and Ultraflex Power Technologies will collaborate on developing an advanced RF (radio frequency) machine. This machine aims to activate cancer treatment nanoparticles for the treatment of metastatic solid tumors through electromagnetic hyperthermia in stage 4 patients. Substantial investments in research institutions, universities, and healthcare centers contribute to the ongoing progress in hyperthermia technology and treatment protocols.

Key Market Players

• Pyrexar Medical
• MagForce AG
• Hydrosun Medizintechnik GmbH
• Andromedic Srl
• YAMAMOTO VINITA CO., LTD
• OncoTherm Kft.
• Nanoprobes, Inc.
• Chongqing Haifu Medical Technology Co., Ltd.
• Novavida Integrative Medical Center
• InnoMedicus Ltd.

Report Scope:

In this report, the Global Hyperthermia Cancer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Hyperthermia Cancer Treatment Market, By Device Type:
• Microwave Hyperthermia Device
• Ultrasound Hyperthermia Device
• Infrared Hyperthermia Device
• Short-wave Hyperthermia Device
• Hyperthermia Cancer Treatment Market, By Application:
• Prostate Cancer
• Breast Cancer
• Cervical Cancer
• Skin Cancer
• Other Cancers
• Hyperthermia Cancer Treatment Market, By End User:
• Hospitals & Clinics
• Specialty Centers
• Others
• Hyperthermia Cancer Treatment Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hyperthermia Cancer Treatment Market.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order. Single User license will be delivered in PDF format without printing rights